Related Experiment Video

Updated: Aug 8, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

The combination of propranolol and magnesium does not prevent postoperative atrial fibrillation

A J Solomon1, A K Berger, K K Trivedi

  • 1Department of Medicine, Georgetown University Medical Center, Washington, DC 20007, USA. solomona@gunet.georgetown.edu

The Annals of Thoracic Surgery
|February 2, 2000
PubMed

Insights

Adjunctive magnesium sulfate did not reduce the incidence of postoperative atrial fibrillation when combined with propranolol in coronary artery bypass patients. This combination therapy did not improve upon beta-blocker efficacy for preventing this common complication.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Atrial fibrillation is a frequent complication following cardiovascular surgery.
  • Beta-blockers are effective in reducing postoperative atrial fibrillation.
  • The role of magnesium in preventing this complication remains debated.

Purpose of the Study:

  • To investigate if magnesium sulfate, when added to propranolol, enhances the prevention of postoperative atrial fibrillation.
  • To evaluate the efficacy of combination therapy versus beta-blocker monotherapy.

Main Methods:

  • A prospective randomized trial involving 167 coronary artery bypass patients.
  • Patients received either propranolol alone or propranolol plus magnesium sulfate.
  • Magnesium administration began intraoperatively, with propranolol initiated in the intensive care unit.

Main Results:

  • Intention-to-treat analysis showed no significant difference in postoperative atrial fibrillation rates between groups (19.5% vs. 22.4%, p = 0.65).
  • Combination therapy led to increased postoperative hypotension, necessitating propranolol dose adjustments.
  • On-treatment analysis also revealed no statistically significant difference in atrial fibrillation incidence (18.5% vs. 10.0%, p = 0.20).

Conclusions:

  • Adjunctive magnesium sulfate does not improve the efficacy of propranolol in preventing postoperative atrial fibrillation.
  • The combination therapy did not demonstrate a significant benefit over propranolol alone.
  • Further research may be needed to explore alternative strategies for atrial fibrillation prevention.
Abstract

More Related Videos

Sterile Pericarditis in Aachener Minipigs As a Model for Atrial Myopathy and Atrial Fibrillation08:56

Sterile Pericarditis in Aachener Minipigs As a Model for Atrial Myopathy and Atrial Fibrillation

Published on: September 24, 2021

Cox-Maze IV Procedure Concomitant with Valvular Surgery In Situs Inversus Dextrocardia: A Single-Center Experience in China08:42

Cox-Maze IV Procedure Concomitant with Valvular Surgery In Situs Inversus Dextrocardia: A Single-Center Experience in China

Published on: February 11, 2022

Related Concept Videos

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...